Navigation Links
Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
Date:12/10/2013

ALISO VIEJO, Calif., Dec. 10, 2013 /PRNewswire/ -- Avanir Pharmaceuticals, Inc. (NASDAQ: AVNR) today announced that PRIME, its phase II clinical trial of the investigational drug AVP-923 (dextromethorphan / quinidine) for the treatment of central neuropathic pain in patients with multiple sclerosis did not meet the primary efficacy endpoint.

(Logo: http://photos.prnewswire.com/prnh/20130207/LA55901LOGO)

In the PRIME study, AVP-923 treated patients experienced levels of pain reduction commensurate with those observed in similar studies and the improvement in pain scores from baseline reached statistical significance; however, there was no difference between the treatment arms and placebo.  Avanir believes that a higher than expected placebo response negatively impacted the study results.  AVP-923 was generally safe and well tolerated.

Avanir plans to review the detailed data from the PRIME study in conjunction with previously generated data in diabetic peripheral neuropathic pain to determine next steps for the development of AVP-923 in neuropathic pain.

About the PRIME Study
The objectives of the PRIME (Pain Research In Multiple sclErosis) study were to evaluate the safety, tolerability, and efficacy of AVP-923 for the treatment of central neuropathic pain in patients with multiple sclerosis. The trial was a multicenter, randomized, double-blind, placebo-controlled, 4-arm parallel group study that enrolled 209 patients. Eligible patients received one of three dose levels of AVP-923 containing either 45mg DM/10 mg Q, 30mg DM/10mg Q, 20mg DM/10mg Q or placebo, daily for 12 weeks. The primary efficacy endpoint was measured based on the Numeric Pain Rating Scale (PRS) as recorded in patient diaries. Primary analysis of this endpoint correlated pain
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
2. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
3. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
4. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
6. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
7. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
8. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
9. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
10. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
11. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)...  The National Association of Drug Diversion Investigators ... Kentucky,s real-time, stop-sale pseudoephedrine ... Precursor Log Exchange (NPLEx) system automatically blocks unlawful ... helps flag meth offenders for law enforcement. Police ... "watch lists" that notify them via email when ...
(Date:10/25/2014)... , Oct. 24, 2014   Metanome, Inc. , ... metagenomic services and data analysis, was the genomic sequencing ... ) Phase I/II clinical trial of SER 109, an ... Clostridium difficile infections (CDI). Metanome ... Health,s R&D and clinical programs. Such genomic characterization has ...
(Date:10/25/2014)... October 24, 2014 ... has announced the addition of the  "Global ...  report to their offering.  ... Chinese Acne Medication Industry Report 2014 is ... current state of the global acne medication ...
Breaking Medicine Technology:Kentucky's NPLEx Technology Making Significant Progress 2Metanome Selected as Metagenomics Provider for Seres Health Clinical Trial 2Global and Chinese Acne Medication Industry Report 2014 2Global and Chinese Acne Medication Industry Report 2014 3
... , SAN DIEGO, Sept. 11 Calixa ... development and commercialization of novel antibiotics for the treatment ... in 20 posters at the Interscience Conference on Antimicrobial ... San Francisco on September 12 to 15, 2009. ...
... , , , ... preliminary schedule of events at the Cardiovascular Research Foundation,s (CRF) ... September 21st to Friday, September 25th, in San Francisco, CA. ... the world,s largest events for those performing cardiac diagnostics and ...
Cached Medicine Technology:Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 2Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 3Calixa Therapeutics to Make Multiple Presentations on CXA-101 and CXA-101/tazobactam at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy 4InfraReDx to Showcase the LipiScan(TM) Coronary Imaging System at the Cardiovascular Research Foundation's (CRF) Annual Transcatheter Cardiovascular Therapeutics (TCT) Scientific Meeting 2
(Date:10/25/2014)... York (PRWEB) October 25, 2014 ... lawsuits ( http://www.vaginalmeshlawsuit2015.com/ ) filed against Boston ... in U.S. District Court, Southern District of West ... Judgment on Punitive Damages in a group of ... a ruling issued on October 21st, U.S. District ...
(Date:10/25/2014)... 2014 Limbkeepers® announced today that they ... with Ed Begley Jr, airing 1st QTR 2015 via ... this episode, Innovations will focus on Limbkeepers® non compression ... thinning skin on arms, hands, and legs from abrasion, ... versatile products, which help reduce injuries, allow for continued ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, 2014 ... -- herpes simplex -- might increase the risk of Alzheimer,s ... being a carrier of certain antibodies to the virus can ... "The identification of a treatable cause [herpes simplex] of ... researcher Dr. Hugo Lovheim, an associate professor in the department ...
(Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- Researchers ... say their findings are cause for concern. ... that are raised for human consumption contribute to ... health, according to background information from the study. ... germs sicken about 2 million people and kill ...
(Date:10/25/2014)... Current osteoporosis screening guidelines and tools fail to ... osteoporosis-related fractures, a new study says. "If ... that help us accurately predict who will suffer ... these at-risk people for preventive measures," study author ... division of general internal medicine and health services ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuits Move Forward, As Federal Judge Denies Motion for Summary Judgment on Punitive Damages in Florida Cases, Bernstein Liebhard LLP Reports 4Health News:Upcoming Episode of Innovations with Ed Begley, Jr. to Feature Limbkeepers® 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Researchers Say Antibiotics in Fish a Health Concern 2Health News:Osteoporosis Screening Guidelines May Miss Younger Women at Risk 2
... Oct. 10 The Johns Hopkins University School,of ... Adjuvant Breast Cancer Strategies: From Biomarkers to Treatment,Selection," ... latest advances in,breast cancer treatment., In recent ... have,led to chemotherapeutic and biologic treatment combinations that ...
... Course for,Non-Dermatologists about Detection and Management of Melanoma, ... the Royal Sonesta Hotel Boston,Cambridge, MA, CONCORD, ... England and the Boston University School of Medicine ... course to update non-dermatologists on the detection and ...
... Nature,s Way Holding Company, a,subsidiary of ... producer of clinically proven phytomedicines, has reached,agreement ... Therapy with North,Castle Partners, LLC, the controlling ... to other shareholders delivering their signatures and,provides ...
... 38 studies found painkillers showed protective effect , , THURSDAY, ... are associated with a reduced risk for breast cancer, ... an invitation for all women to start popping the ... that to happen here, for people to jump on ...
... care, deliver higher, levels of documentation accuracy, and increase staff ... ... PITTSBURGH, Oct. 9 Vocollect Healthcare Systems, Inc.,announces that Community ... care as part of its,strategic initiative to deliver the utmost ...
... 9 ATS Medical, Inc.,(Nasdaq: ATSI ), ... today that it will participate at the Second,Annual ... Astoria,in New York. Michael Dale, President and CEO ... Time on Monday, October 13, 2008., (Logo: ...
Cached Medicine News:Health News:Latest Research on Breast Cancer Presented in a Virtual E-Conference CME Course 2Health News:Paul Sullivan's Legacy: An Early Warning Program for Detecting Melanoma Before It's Too Late 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 2Health News:Schwabe, World Leader in Herbal Manufacturing Will Acquire Enzymatic Therapy Through Nature's Way Holding, Inc. 3Health News:NSAIDs Might Lower Breast Cancer Risk 2Health News:NSAIDs Might Lower Breast Cancer Risk 3Health News:Community Eldercare Services LLC Deploys Voice-Assisted Care to Revolutionize Care Across Its 20-Facility Enterprise 2Health News:Community Eldercare Services LLC Deploys Voice-Assisted Care to Revolutionize Care Across Its 20-Facility Enterprise 3Health News:ATS Medical to Participate at the Natixis Bleichroeder Second Annual Hidden Gems Conference 2
... watt halogen light source with ... ,SOLOS Endoscopy shares your commitment ... the highest quality care available ... development of advanced surgical instruments ...
Linvatecs single CCD camera heads offer high resolution with the convenience of programmable buttons for sterile field control of the printer and VCR. Available in "V and "C mount in NTSC and PAL....
... camera system offers the latest technology ... controller. Equipped with many of the ... expensive camera controllers, including edge enhancement, ... The controller is compatible and interchangeable ...
... Camera Systems provide the advanced functionality ... need for advanced training. Programmable, easy ... the flexibility needed to accommodate the ... Compatible with both autoclavable and non-autoclavable ...
Medicine Products: